TFX Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -17.18% compared to Teleflex's net margin of --. Teleflex's return on equity of 1.57% beat Perspective Therapeutics's return on equity of --.

Teleflex has a consensus price target of $168.21, signalling upside risk potential of 18.83%. On the other hand Perspective Therapeutics has an analysts' consensus of $15.58 which suggests that it could grow by 518.13%. Given that Perspective Therapeutics has higher upside potential than Teleflex, analysts believe Perspective Therapeutics is more attractive than Teleflex.

Teleflex has a beta of 1.211, which suggesting that the stock is 21.134% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.251, suggesting its more volatile than the S&P 500 by 25.149%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 0.96%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex pays 91.2% of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $795.4M, which are larger than Perspective Therapeutics quarterly revenues of --. Teleflex's net income of -$136.7M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Teleflex's price-to-earnings ratio is 99.69x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.19x versus 13.61x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of -17.18% compared to Teleflex's net margin of 28.41%. Teleflex's return on equity of 1.57% beat Intuitive Surgical's return on equity of 15.6%.

Teleflex has a consensus price target of $168.21, signalling upside risk potential of 18.83%. On the other hand Intuitive Surgical has an analysts' consensus of $626.53 which suggests that it could grow by 27.22%. Given that Intuitive Surgical has higher upside potential than Teleflex, analysts believe Intuitive Surgical is more attractive than Teleflex.

Teleflex has a beta of 1.211, which suggesting that the stock is 21.134% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.616%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 0.96%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex pays 91.2% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $795.4M, which are smaller than Intuitive Surgical quarterly revenues of $2.4B. Teleflex's net income of -$136.7M is lower than Intuitive Surgical's net income of $685.7M. Notably, Teleflex's price-to-earnings ratio is 99.69x while Intuitive Surgical's PE ratio is 76.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.19x versus 21.35x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -17.18% compared to Teleflex's net margin of 26.88%. Teleflex's return on equity of 1.57% beat ResMed's return on equity of 25.56%.

Teleflex has a consensus price target of $168.21, signalling upside risk potential of 18.83%. On the other hand ResMed has an analysts' consensus of $270.09 which suggests that it could grow by 22.94%. Given that ResMed has higher upside potential than Teleflex, analysts believe ResMed is more attractive than Teleflex.

Teleflex has a beta of 1.211, which suggesting that the stock is 21.134% more volatile than S&P 500. In comparison ResMed has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.22%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 0.96%. ResMed offers a yield of 0.94% to investors and pays a quarterly dividend of $0.53 per share. Teleflex pays 91.2% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $795.4M, which are smaller than ResMed quarterly revenues of $1.3B. Teleflex's net income of -$136.7M is lower than ResMed's net income of $344.6M. Notably, Teleflex's price-to-earnings ratio is 99.69x while ResMed's PE ratio is 25.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.19x versus 6.58x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services has a net margin of -17.18% compared to Teleflex's net margin of 17.38%. Teleflex's return on equity of 1.57% beat West Pharmaceutical Services's return on equity of 18.15%.

Teleflex has a consensus price target of $168.21, signalling upside risk potential of 18.83%. On the other hand West Pharmaceutical Services has an analysts' consensus of $285.01 which suggests that it could grow by 24.63%. Given that West Pharmaceutical Services has higher upside potential than Teleflex, analysts believe West Pharmaceutical Services is more attractive than Teleflex.

Teleflex has a beta of 1.211, which suggesting that the stock is 21.134% more volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.088, suggesting its more volatile than the S&P 500 by 8.847%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 0.96%. West Pharmaceutical Services offers a yield of 0.36% to investors and pays a quarterly dividend of $0.21 per share. Teleflex pays 91.2% of its earnings as a dividend. West Pharmaceutical Services pays out 12% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $795.4M, which are larger than West Pharmaceutical Services quarterly revenues of $748.8M. Teleflex's net income of -$136.7M is lower than West Pharmaceutical Services's net income of $130.1M. Notably, Teleflex's price-to-earnings ratio is 99.69x while West Pharmaceutical Services's PE ratio is 34.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.19x versus 5.83x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.